Pharmacogenetic studies of epilepsy drugs: are we there yet?
One of the mantras of scientists working in the field of pharmacogenetics is 'the right dose for the right patient'. A recent article has gone someway towards demonstrating that this goal can be achieved using genetic approaches. It is one of the first reports to show that a specific polymorphism can predict the maximum tolerated dose of two anti-epileptic drugs. However, further studies are necessary to validate these observations.
Spurr
Nigel K
NK
Genetics Research, GlaxoSmithKline R&D, New Medicines Research Centre, Stevenage, Herts, UK, SG1 2NY.
D004305:Dose-Response Relationship, Drug; D004358:Drug Therapy / Q000379:methods*; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends*; D011110:Polymorphism, Genetic